Analysts expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to post earnings of ($0.65) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Protagonist Therapeutics’ earnings. The lowest EPS estimate is ($0.70) and the highest is ($0.59). Protagonist Therapeutics reported earnings of ($0.36) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 80.6%. The business is scheduled to announce its next quarterly earnings results on Wednesday, May 8th.

According to Zacks, analysts expect that Protagonist Therapeutics will report full-year earnings of ($2.77) per share for the current financial year, with EPS estimates ranging from ($3.06) to ($2.47). For the next financial year, analysts expect that the firm will post earnings of ($2.86) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The company had revenue of $2.35 million for the quarter, compared to the consensus estimate of $5.45 million. Protagonist Therapeutics had a negative return on equity of 33.94% and a negative net margin of 125.87%.

PTGX has been the subject of several recent analyst reports. ValuEngine raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, March 25th. Zacks Investment Research raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 26th. BidaskClub cut Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 13th. Finally, BMO Capital Markets initiated coverage on Protagonist Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $17.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $15.45.

In related news, CEO Dinesh V. Ph D. Patel sold 10,909 shares of the stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total transaction of $84,435.66. Following the completion of the sale, the chief executive officer now directly owns 367,396 shares in the company, valued at $2,843,645.04. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Y. Liu sold 3,821 shares of the stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total value of $29,574.54. Following the sale, the insider now owns 37,007 shares of the company’s stock, valued at $286,434.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,570 shares of company stock valued at $136,815. 13.80% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. raised its holdings in shares of Protagonist Therapeutics by 75.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after acquiring an additional 8,450 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Protagonist Therapeutics by 94.3% during the fourth quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after acquiring an additional 12,819 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Protagonist Therapeutics by 17.2% during the fourth quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after acquiring an additional 5,084 shares in the last quarter. Tibra Equities Europe Ltd purchased a new stake in shares of Protagonist Therapeutics during the first quarter worth $410,000. Finally, Barclays PLC purchased a new stake in shares of Protagonist Therapeutics during the fourth quarter worth $462,000. Institutional investors and hedge funds own 59.51% of the company’s stock.

Shares of PTGX traded down $0.17 during trading hours on Wednesday, hitting $10.30. 971 shares of the company were exchanged, compared to its average volume of 215,603. The firm has a market cap of $240.41 million, a PE ratio of -5.92 and a beta of 2.19. Protagonist Therapeutics has a one year low of $5.49 and a one year high of $14.36.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Further Reading: Are sell-side analysts objective?

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.